Navigation Links
Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
Date:5/31/2008

.3 mg/m2 on days 1, 4, 8 and 11, and dexamethasone at 40 mg on days 1 through 4, 9 through 12, and 17 through 20 of a 28-day schedule. A total of four cycles was planned with a goal of proceeding on to stem cell transplant (SCT). Results were presented by Craig Reeder, M.D., Assistant Professor of Medicine, Mayo Clinic College of Medicine, and showed a CR rate of 46 percent prior to transplant, a CR rate of 72 percent post-transplant and an overall response rate (partial response or better) of 95 percent. Side effects included thrombocytopenia, neutropenia, hyperglycemia and peripheral neuropathy.

VELCADE, Pegylated-Lyposomal-Doxorubicin and dexamethasone (PAD or VcDD) as Induction Therapy Prior to Reduced Intensity ASCT Followed by Lenalidomide and Prednisone (LP) as Consolidation and Lenalidomide Alone as Maintenance (Abstract #8518)

This study of PAD (VcDD) was designed to evaluate the VELCADE combination as induction therapy prior to SCT in patients with newly diagnosed multiple myeloma. The results showed the status of 86 evaluable patients who received VELCADE at 1.3 mg/m2 on days 1, 4, 8, 11, DOXIL at 30 mg/m2 on day 4 and dexamethasone at 40 mg on days 1 through 4, 8 through 11, 15 through 18 for one cycle and on days 1 through 4 for cycles two through four. Cyclophosphamide at 3 g/m2 and G-CSF were used to harvest stem cells. Patients were then conditioned with two courses of melphalan at 100 mg/m2 (MEL100). Following SCT, patients received lenalidomide at 25 mg/day on days 1 through 21 plus prednisone at 50 mg every other day for four, 28-day LP cycles. This was followed by lenalidomide alone at 10 mg/day on days 1 through 21 every 28 days. Results were presented by Antonio Palumbo, M.D., Chief of the Myeloma Unit; Department of Hematology, University of Torino and showed 94 percent of patients achieved at least a partial response, including a CR rate of 21 percent after four cycles of VcDD. Post transplant, the CR rate increased to 59 percen
'/>"/>

SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Today, ... that modify the religious "accommodation" but still require ... that have an abortifacient effect, including Plan B ... after pill"). The Obama Administration also announced that ... closely held, for-profit corporations. The regulations ...
(Date:8/22/2014)... Aug. 22, 2014  Dr. Mark Rasak , ... Diamond Lifetime Achievement Award in the field of Medicine ... Cardiovascular Clinical Associates. Dr. Rasak has over ... major aspects of the business; overseeing the daily operations; ... coronary intervention. In addition, he is an honored Fellow ...
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research ... shows that a therapy being developed by Hera Therapeutics Inc. ... cause 70 percent of all cervical cancer. When ... replication of HPV-16, HPV-18 and HPV-11 cells, according to ... Ph.D., who presented the findings at the Seattle ...
Breaking Medicine Technology:Liberty Institute: Government "Accommodation" Still Requires Employers To Facilitate Coverage Of Abortifacient Drugs 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... At its regularly scheduled meeting on September 14, ... (the "Company" or "AMPAC") (Nasdaq: APFC ) ... that shareholders at the next Annual Meeting amend AMPAC,s ... for director election with a simple majority vote requirement. ...
... U.S. Food and Drug Administration (FDA), working in close ... announced that Forest Pharmaceuticals, Inc. entered into a plea ... actions including distribution of an unapproved new drug, distribution ... inspection. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:American Pacific Adopts Corporate Governance Changes 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 2Forest Pharmaceuticals Agrees to Guilty Plea for Violating FDA Laws 3
(Date:8/23/2014)... 23, 2014 Legal Insider Bot ... by Greg Marks has been generating a buzz of ... The commotion surrounding the new product has drawn the ... , “In recent years the market has ... commonly referred to as robots or ‘bots,'” reports Hendricks. ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
(Date:8/23/2014)... August 23, 2014 Professional kitchen employees, ... study aid in preparing for Food Safety Certification exams ... by Dynamic Path. , Dynamic Path announced the ... includes more than 200 review questions for culinary industry ... designed to cover requirements of the ServSafe® Food Safety ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Young adults in Athens, ... doing drugs should pick up the phone and call the new ... teen drug addict . , Troubled Teen Athens is a ... ready to finally take the necessary steps to end substance abuse ... are quick to go to friends or peers when really they ...
(Date:8/23/2014)... 23, 2014 Youth substance abuse is ... no different in Houston, TX. Substance abuse can happen ... to drug and alcohol dependency in higher numbers than ... beat substance abuse, but don’t know where to find ... can be a challenge because most treatment options are ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... of the population but account for nearly 20 percent ... major risk factor for // suicide in the elderly. ... thoughts in depressed elderly patients. ,Researchers from ... 600 elderly patients with depression. Some patients were assigned ...
... skin’s worst enemies, but now some dermatologists are taking cues from sunlight ... phototherapy. ,Standing in front of a UV light is ... from a disease called morphea , it can affect any area of ... joints, also known as localized scleroderma. She says: “I had a bunch ...
... can be a significant predictor of breast cancer risk for ... ,In 1992, researchers sampled nearly 62,000 women, ages ... age 18 and their current weight. Since then, the women ... in addition to any diagnosis of cancer. Research shows ...
... Around 165,000 cases of lung cancer are diagnosed in ... to 25 percent are classified // as small cell ... and the disease frequently travels to the brain and ... cancer, for example, ranges up to 80 percent. Whether ...
... a new drug is showing promising results.For the past ... recombinant immunotoxins. An immunotoxin is bioengineered and consists of ... antibodies that are commonly used to fight leukemia. One ... a phase II study. ,Researchers say in a ...
... A recent study has shown that a chemotherapy regimen ... prednisone is effective in the treatment of hormone-refractory prostate ... to symptomatic patients earlier in their disease. ... study of this treatment regimen is planned. From a ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Sterile cordless eraser tips, packsize is 10/box....
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Bi-angled insertion jaws designed to enhance surgeon comfort and efficiency. Reverse action releases lens when handle is compressed. Made in titanium....
45 degree. Angled shafts. Tip to angle length: 11.5 mm. Stops in handle designed to prevent "over folding". Manufactured in titanium....
Medicine Products: